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CO R R E S POND EN C E : O U R E X P E R I E N C E
Squamous cell carcinoma of the temporal bone in 30 patients:
Difference in presentation and treatment in de novo disease
vs radiation associated disease1
1 | INTRODUCTION4
Squamous cell carcinoma temporal bone (SCCTB) is a rare malig-
nancy with incidence of around 1 to 1.2 case per million populations
per year. Risk factors included chronic otitis media and chronic irrita-
tion of the skin and mucosa of the external and middle ear.1 A rare
but important aetiology is radiation to the region for treatment of
head and neck malignancies. Radiation treatment for nasopharyngeal
carcinoma (NPC) appears an important association of post-irradiated
SCC of temporal bone in South-East Asia as demonstrated by previ-
ous reported cohorts from Taiwan and Singapore.2-4
This study investigates and compares the presentation, treatment
and prognosis of de novo SCCTB (dnSCC) and post-irradiated
SCCTB (piSCC). We investigate whether prior irradiation to the
region would limit on treatment options and leading to difference in
survival and local disease control of piSCC compared to dnSCC.
2 | METHODS
We reviewed our department’s database and retrieved all temporal
bone squamous cell carcinoma treated from June 1995 to June
2016. Only patients with complete clinical data were included. The
study was approved by our hospital’s ethics committee.
All patients have histological diagnosis of SCC of the external
auditory canal or mastoid. SCC of the auricle and pinna was
excluded. 36.7% patients had MRI scan in addition to CT scan per-
formed for tumour staging. In our institute, all the patients with NPC
were followed up lifelong by the otorhinolaryngologist.
We analysed the clinical characteristics and treatment outcome
and further divided the patients into de novo group (dnSCC) with no
prior radiation to the head and neck region and the piSCC, who all had
received radiation treatment. Post-irradiation malignancy is defined as
development of a new malignancy with different histology within the
field of previous radiation treatment diagnosed after a latent period of
5 years, and which is histologically different from the initial malig-
nancy.5 Modified Pittsburgh Classification6 was used to stage the SCC
temporal bone.6 Comparisons were made on the stage at presentation,
disease-free survival (DFS) and overall survival (OS).
All data were collected retrospectively. SPSS version 23 was used
for analysis. Kaplan-Meier plot and log rank test are used for survival
analysis. Mann-Whitney U test for continuous variables and the
Fisher’s exact test for categorical variables were used for analysis. A
P value of less than .05 was considered as significant.
3 | RESULTS
3.1 | Patient demographics
From June 1995 to June 2016, 30 cases of temporal bone SCC were
treated in our institution, of which 16 (53.3%) were piSCC and 14
(46.7%) were dnSCC. All the patients in piSCC group received radia-
tion treatment for NPC.
There was no difference in baseline characteristics (Table 1A).
Mean age of SCC presentation was 64.8 years old. In the piSCC
group, the mean age of diagnosis of the NPC was 48.3 years old.
Male pre-dominance was observed in both groups.
10% of the tumour has initial negative biopsy result, including
squamous papilloma, inflamed granulation tissue, cholesteatoma and
inflammatory polyp. Histological diagnosis of SCC temporal bone
was confirmed in later biopsy or operative specimen.
The median latency period of piSCC is 16.8 years, ranges from
5.76 to 29.1 years. It is consistent with previous reports that the
median latency period of piSCC is 17-18.8 years and can be as long
as three decades.3,4
In our current cohort, bilateral sequential piSCC of temporal bone
occurred in one male and one female patient with NPC, the latency
period is 12.6 year and 10.0 year, respectively. The first incidence of
SCC temporal bone of the female patient occurred in 1992; therefore,
the episode was excluded from the current cohort. The incidence of
sequential contralateral piSCC of temporal bone is 13.3%.
3.2 | Stage of disease at presentation
Majority of patients presented late at Pittsburg T3 and T4 disease,
constituting 27% and 36% of the whole cohort, respectively. Post-
irradiated SCCTB presented significantly earlier with lower Pittsburg
T-stage and overall stage. Two patients in the piSCC group pre-
sented early with Tis disease. (Table 1B).
Lymph node metastasis is uncommon at presentation, in which
only two patients (7%) had N2 disease at presentation. There was
no statistical difference in the initial N Stage (Table 1B).
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3.3 | Treatment
Two patients received radiotherapy alone and one patient received
chemo-radiation alone. 25 cases were treated with curative intent
surgery and two cases in the piSCC group were treated with pallia-
tive surgery for pain relief: 11 (40.7%) radical mastoidectomies, 10
(37.0%) lateral temporal bone resections and six (22.2%) subtotal
temporal bone resections. Resection margin was positive or close in
six patients with piSCC (42.9%) and seven patients with dnSCC
(50.0%). The commonest involved margins are the deep and/ or
superior margin, occurring in 69.2% cases of involved margins.
Neck dissection was performed on the two patients who pre-
sented with lymph node metastasis and one patient requiring free
flap reconstruction. Elective neck dissection was not performed in
patients with N0 disease. Two patients received additional
parotidectomy and two patients received condylectomy for tumours
extending anteriorly to the parotid or temporomandibular joint.
Adjuvant radiotherapy or chemoradiotherapy were offered to
patients with T3 or T4 tumour or positive resection margins, where
the decision for adjuvant treatment was made in multidisciplinary
meeting involving oncologist and surgeons. Nevertheless, five of
seven patients in piSCC group (71.4%) refused adjuvant radiotherapy
after discussion with oncologist due to toxicity of the additional sec-
ond or third course of radiotherapy when majority had already suf-
fered from significant complication of prior radiation for NPC.
Significantly more patients (84.6%) in dnSCC group received post-
operative adjuvant treatment comparing to only 14.3% of the piSCC
group (Table 26 ).
3.4 | Outcome
The follow-up period ranged from five to 245 months. Estimated
median OS, disease-specific survival (DSS) and DFS of the whole
cohort were 45, 48 and 18 months, respectively.
Median OS of dnSCC group and piSCC group is 23 months (95%
CI: 0-54.8 months) and 48 months (95% CI: 33.4-62.6 months),
respectively (Figure 1A). Median DSS of dnSCC group and piSCC
group is 43 months (95% CI: 43.0-56.0 months) and 56 months
(95% CI: 37.0-75.0 months), respectively (Figure 1B). There was no
statistical difference in the OS and DSS between the dnSCC and
piSCC group despite early T-stage diseases in the piSCC group.
As expected, OS and DFS are significantly better in tumour with
lower T-stage. The 3-year OS of T2 or lower stage is 100%. 3-year
OS survival markedly reduced to 50% for T3 tumour and 31.2% for
T4 tumour (Figure 2A). Similarly, 3-year DFS of Tis and T1 tumour
achieved 100%, and T2 tumour has achieved 75% (Figure 2B).
TABLE 1 XXXXX12
5
Whole
cohort dnSCC
Post-irradiated
SCCTB P value
Age of diagnosis (y)
Mean 64.8 64.0 65.5 .754
Range 46-84.5 46-84.5 49.3-80.2
Gender
Male 23 11 13 .63
Female 6 3 3
History of chronic
ear infection
10 2 8 .277
TABLE 2 XXXXX
Whole
cohort dnSCC
Post-irradiated
SCCTB P value
T stage (%)
Tis 2 (7) 0 (0) 2 (12) .034
T1 4 (13) 1 (7) 3 (19)
T2 5 (17) 1 (7) 4 (25)
T3 8 (27) 5 (36) 3 (19)
T4 11 (36) 7 (50) 4 (25)
N stage (%)
N0 28 (93) 12 (86) 16 (100) .124
N1 0 (0) 0 (0) 0 (0)
N2 2 (7) 2 (14) 0 (0)
Overall stage (%)
Stage 0 2 (7) 0 (0) 2 (12) .023
Stage I 4 (13) 1 (7) 3 (19)
Stage II 5 (17) 1 (7) 4 (25)
Stage III 7 (23) 4 (29) 3 (19)
Stage IV 12 (40) 8 (57) 4 (25)
Keypoints
• History of nasopharyngeal carcinoma (NPC) is the most
important cause of post-irradiated SCCTB (piSCC) of the
temporal bone in locality where NPC is endemic, includ-
ing Hong Kong.
• Bilateral sequential piSCC in NPC survivors is not
uncommon. 13% of patient with piSCC in our series has
bilateral disease.
• Long latency period of piSCC indicates lifelong surveil-
lance of patients with NPC might be necessary, in which
early detection can be achieved as demonstrated in our
series.
• Lower T-stage and overall stage can translate to superior
overall and DFS of SCC temporal bone.
• Prognosis of piSCC and dnSCC remains similar despite
early detection of piSCC in our series, which may be
attributed by the limitation in administration of adjuvant
treatment in patients with piSCC, and therefore, achiev-
ing a negative surgical margins is seemed to offer best
outcome for patients with piSCC temporal bone.
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
2 | CORRESPONDENCE: OUR EXPERIENCE
None of the patients with piSCC develop distant or nodal metas-
tasis within the follow-up period, comparing to 35.7% in the dnSCC
group.
4 | DISCUSSION
Nasopharyngeal carcinoma is prevalent in Hong Kong. According to
the Hong Kong Cancer Registry, yearly incidence of NPC in our
locality ranges from 800-900. Prior radiation therapy for NPC is the
most common cause of piSCC temporal bone in Hong Kong, consti-
tuting all cases in our series.
Due to rarity of disease, management strategies were guided
by limited number of available cohort series and literature
reviews.7-9 In particular, limited information on piSCC was avail-
able in the literature—Lim et al. first reported five cases in 2000.2
Lo et al.3 reported 10 cases in 2008, and Tay el al.4 reported
eight cases in 2014. All the three cases series were NPC sur-
vivors. Most recently in 2015, Lambert et al.10 from MD Anderson
Cancer Centre in US reported nine cases, which a proportion of
the primary tumours were not NPC. Treatment strategies for
F IGURE 110 (A) Kaplan-Meier survival curve showing overall
survival in piSCC group compared with dnSCC group. P=.887, log
rank test; (B) Kaplan-Meier survival curve showing disease-specific
survival in piSCC group compared with dnSCC group. P=.803, log
rank test; (C) Kaplan-Meier survival curve showing disease-free
survival in piSCC group compared with dnSCC group. P=.562, log
rank test%
F IGURE 2 11(A) Kaplan-Meier survival curve showing overall
survival of SCC temporal bone categorized in T stage. P=.023, log rank
test; (B) Kaplan-Meier survival curve showing disease-free survival of
SCC temporal bone categorized in T stage. P=.014, log rank test
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example the choice of surgical approach with en bloc vs piece-
meal dissection, need of elective parotidectomy, need of elective
neck dissection, effectiveness of chemotherapy were much
debated and remained controversial.7-9
Although adjuvant radiation is generally indicated in SCCTB of
advanced stage or aggressive features,8 further irradiation to piSCC is
limited by previous radiation exposure of the temporal bone. Patients
with post-irradiated NPC tolerated further irradiation poorly. In the
series by Lo et al.,1 50% of the patients with piSCC received further
adjuvant radiotherapy (50-60 Gy) died of radiation complication (two
massive epistaxis, one temporal bone osteoradionecrosis). Therefore,
surgery remains the mainstay of treatment in this group of patient,
with achieving a negative surgical margins seemed to offer the best
outcome for patients with PISCC of the ear.4
In the present cohort, piSCC group of patients presents with ear-
lier disease then dnSCC group. This may be due to the regular follow
up of the patients with NPC by otolaryngologist and early biopsy of
suspicious lesions in the ear. On the contrary, patients with dnSCC
usually have chronically discharging ears that they elect to disregard
the symptoms and not seek medical care until when symptoms of
more advance disease like pain and significant bleeding occur.
It would be expected that with earlier presentation, the piSCC
group should enjoy a better survival. However, adjuvant radiation
was usually not given to piSCC group of patients after radical sur-
gery to avoid excessive toxicity to the surrounding tissue. The lack
of adjuvant radiation in the piSCC group may explain the similar dis-
ease control and survival despite earlier presentation of the disease.
As the anatomy of the temporal bone is complex with many vital
structures in proximity, a true negative resection margins may not be
easily achieve and adjuvant radiation may have a role in controlling
the microscopic residual diseases.
Survival of piSCC is generally poor, the 3-year OS ranges from
20%-60%. Literature data on comparison prognosis of piSCC and
dnSCC remained inconsistent. Lo et al.3 in 2000 suggested inferior
prognosis in patients with piSCC, whereas latest series in 2014 by
Tay et al.4 suggested similar prognosis between the two groups.
Optimal treatment strategy and surgical approach still remains
controversial.
Role of elective neck dissection and parotidectomy is controver-
sial.7-9 In our series, all patients with piSCC did not receive elective
neck dissection and elective parotidectomy. No patients with piSCC
develop nodal or distant metastasis. Therefore, elective neck dissec-
tion and elective parotidectomy in patients with prior irradiation to
the neck are not recommended.
This is the largest cohort of temporal bone SCC occurring in
patient who had prior radiation to the head and neck region reported
in the literature. Nevertheless, retrospective nature subjects the study
to misclassification and information bias. Data collection spans over
15 years, 3-D conformal RT has emerged as the treatment of choice
over the years and the choice of surgical treatment by en bloc vs
piecemeal surgery was based on the discretion of surgeon. Histologi-
cal assessment of margins was non-standardised and it is difficult to
ascertain the surgical margins in case of piecemeal resection.
5 | CONCLUSION
Post-irradiated SCCTB of temporal bone is rare but important compli-
cation in NPC patients with prolonged survival. Majority, if not all
piSCC in our locality occur in patients with history of NPC. Long
latency period of the disease indicates lifelong surveillance of patients
with NPC might be necessary. It is important to be aware of bilateral
sequential piSCC as it can occur in up to 13% of patients.
Early detection can be achieved in long-term survival as demon-
strated in our series. High index of suspicion is required due to the
inconspicuous signs and symptoms as well as possible initial false-
negative biopsy result. Although lower T-stage and overall stage can
translate to superior overall and DFS, prognosis of piSCC and dnSCC
remains similar. It may be attributed by limitation in administration of
adjuvant treatment in patients with piSCC. Elective neck dissection
and parotidectomy are not recommended in patients with prior irradia-
tion to neck.
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